文献速递类风湿关节炎其他结缔组织病

VAR-EPIDSER研究:类风湿关节炎间质性肺病筛查标准在常规临床实践中的验证

Validation of screening criteria for interstitial lung disease in rheumatoid arthritis in routine clinical practice: the VAR-EPIDSER study.
PubMed 文献 · RMD Open · 2026-05-18

该多中心横断面研究在西班牙15家医院纳入477例无既往ILD诊断的RA患者,应用AR-EPIDSER筛查标准并以胸部高分辨率CT(HRCT)为参考。HRCT可评估的424例中ILD患病率为13.0%,亚临床ILD占63.6%;筛查标准灵敏度0.93、特异度0.36、阳性预测值0.18、阴性预测值0.97。结论为未诊断ILD常见且多无症状,该标准因高灵敏度和极佳阴性预测值适合初筛,但阳性者需HRCT确认。

要点

  • RA患者中HRCT检出的ILD患病率为13.0%,其中亚临床ILD占63.6%。
  • AR-EPIDSER筛查标准灵敏度0.93、阴性预测值0.97,适合作为初筛工具。
  • 该标准特异度仅0.36,阳性预测值0.18,筛查阳性者需HRCT确认。

核心结论

  • 在西班牙RA患者中,未诊断的ILD常见且大多为亚临床型。
  • AR-EPIDSER标准因高灵敏度和极佳阴性预测值可作为初始筛查工具,但低特异度提示阳性病例需HRCT确认。

研究设计与样本

  • 多中心横断面观察性研究,在西班牙15家医院开展。
  • 纳入符合ACR 1987或ACR/EULAR 2010标准且无既往ILD诊断的成年RA患者。
  • 所有参与者接受胸部HRCT作为参考试验并集中阅片,共477例招募、424例HRCT可评估。

主要发现

  • HRCT可评估的424例中,ILD患病率为13.0%(55/424;95%CI 9.9%至16.6%)。
  • 亚临床ILD(无咳嗽、呼吸困难或Velcro样啰音)为8.3%(35/424;95%CI 5.7%至11.1%),占ILD病例的63.6%。
  • 筛查阳性者占68.2%(289/424)。
  • AR-EPIDSER标准灵敏度=0.93(95%CI 0.82至0.98),特异度=0.36(95%CI 0.31至0.41)。
  • 阳性预测值=0.18(95%CI 0.13至0.23),阴性预测值=0.97(95%CI 0.93至0.99)。

关键数值与推荐

  • AR-EPIDSER筛查标准灵敏度0.93(95%CI 0.82至0.98)、特异度0.36(95%CI 0.31至0.41)。
  • 阳性预测值0.18(95%CI 0.13至0.23),阴性预测值0.97(95%CI 0.93至0.99)。

临床怎么用

  • 对无既往ILD诊断的RA患者可应用AR-EPIDSER标准进行初筛,阴性结果有助于排除ILD。
  • 筛查阳性者应通过胸部HRCT确认,因标准特异度和阳性预测值较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the validity of the rheumatoid arthritis-interstitial lung disease screening project of the Spanish Society of Rheumatology (AR-EPIDSER) screening criteria for detecting rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) and to estimate the prevalence of undiagnosed and subclinical ILD in patients with RA in Spain. PATIENTS AND METHODS: Multicentre cross-sectional observational study conducted in 15 Spanish hospitals. Adult patients with RA (American College of Rheumatology (ACR) 1987 or ACR/European Alliance of Associations for Rheumatology 2010 criteria) without a previous ILD diagnosis were included. During a rheumatology visit, the AR-EPIDSER screening criteria were applied, and all participants underwent high-resolution CT (HRCT) of the chest as the reference test, with centralised reading. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were estimated with 95% CI as well as the prevalence of ILD and subclinical ILD. RESULTS: A total of 477 patients were recruited; 424 had evaluable HRCT (73.6% women; median age 59 years). The prevalence of ILD on HRCT examinations was 13.0% (55/424; 95% CI 9.9% to 16.6%). Subclinical ILD (no cough, dyspnoea or 'Velcro-like' crackles) was 8.3% (35/424; 95% CI 5.7% to 11.1%), accounting for 63.6% of ILD cases. Screening was positive in 68.2% (289/424). The AR-EPIDSER criteria showed sensitivity=0.93 (95% CI 0.82 to 0.98), specificity=0.36 (0.31 to 0.41), PPV=0.18 (0.13 to 0.23) and NPV=0.97 (0.93 to 0.99). CONCLUSION: In Spanish patients with RA, undiagnosed ILD is frequent and mostly subclinical. The AR-EPIDSER criteria are useful as an initial screening tool due to high sensitivity and excellent NPV; however, low specificity suggests that positive cases should be confirmed by HRCT.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mena-Vázquez N, Domínguez-Álvaro M, Bonilla Hernán MG, et al. Validation of screening criteria for interstitial lung disease in rheumatoid arthritis in routine clinical practice: the VAR-EPIDSER study. RMD Open. 2026. PMID: 42150840. doi:10.1136/rmdopen-2026-006934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。